These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 10502808

  • 1. Cancer vaccine strategies get bigger and better.
    de Gruijl TD, Curiel DT.
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract] [Full Text] [Related]

  • 2. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.
    Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
    [Abstract] [Full Text] [Related]

  • 3. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 4. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 5. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 6. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 7. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H.
    Clin Cancer Res; 2007 Mar 01; 13(5):1503-10. PubMed ID: 17332295
    [Abstract] [Full Text] [Related]

  • 8. Excitement tempered by long road ahead for dendritic cell vaccines.
    Vanchieri C.
    J Natl Cancer Inst; 2004 Sep 15; 96(18):1350-1. PubMed ID: 15367563
    [No Abstract] [Full Text] [Related]

  • 9. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K.
    J Cancer Res Clin Oncol; 2001 Oct 15; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract] [Full Text] [Related]

  • 10. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
    Ansell SM, Suman VJ.
    J Clin Oncol; 2011 Jul 10; 29(20):2748-9. PubMed ID: 21632499
    [No Abstract] [Full Text] [Related]

  • 11. Personalized vaccine for newly diagnosed follicular non-Hodgkin's lymphoma.
    Clin Adv Hematol Oncol; 2003 Jan 10; 1(1):66. PubMed ID: 16227965
    [No Abstract] [Full Text] [Related]

  • 12. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer.
    Lim M, Simons JW.
    Curr Opin Mol Ther; 1999 Feb 10; 1(1):64-71. PubMed ID: 11249686
    [No Abstract] [Full Text] [Related]

  • 13. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv.
    Clin Cancer Res; 2007 Mar 01; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract] [Full Text] [Related]

  • 14. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR.
    Future Oncol; 2011 Jan 01; 7(1):111-22. PubMed ID: 21174542
    [Abstract] [Full Text] [Related]

  • 15. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M, Hodi FS, Dranoff G.
    Immunol Rev; 2008 Apr 01; 222():287-98. PubMed ID: 18364009
    [Abstract] [Full Text] [Related]

  • 16. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract] [Full Text] [Related]

  • 17. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
    Mellstedt H, Osterborg A.
    Pathol Biol (Paris); 1999 Feb 20; 47(2):211-5. PubMed ID: 10192891
    [Abstract] [Full Text] [Related]

  • 18. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M.
    Curr Opin Mol Ther; 2008 Oct 20; 10(5):526-34. PubMed ID: 18830928
    [Abstract] [Full Text] [Related]

  • 19. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Bendandi M.
    Expert Rev Anticancer Ther; 2001 Jun 20; 1(1):65-72. PubMed ID: 12113135
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q.
    Expert Rev Vaccines; 2003 Jun 20; 2(3):391-8. PubMed ID: 12903804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.